Medtronic’s campaign to secure FDA approval – Symplicity Spyral – has been anything but simple.
But in this episode of the MedtronicTalks podcast, Jason Weidman, senior vice president and president of Coronary & Renal Denervation, explains why the company has refused to give up the fight to develop the renal denervation tool to lower hypertension.
Weidman explains why the company couldn’t share updated clinical data this fall as it hoped and he gives a new timeframe for the next milestone.